Five Prime Therapeutics buy melinda
Start price
21.08.18
/
50%
€12.08
Target price
20.09.18
€13.98
Performance (%)
6.80%
End price
20.09.18
€12.90
Summary
This prediction ended on 20.09.18 with a price of €12.90. The BUY prediction by melinda finished with a performance of 6.80%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Five Prime Therapeutics | - | - | - | - |
| iShares Core DAX® | -0.552% | 3.281% | 15.052% | 17.017% |
| iShares Nasdaq 100 | -1.415% | 4.535% | 26.243% | 54.337% |
| iShares Nikkei 225® | -0.877% | -1.739% | 4.897% | 4.751% |
| iShares S&P 500 | -0.415% | 3.239% | 23.253% | 46.758% |
Comments by melinda for this prediction
In the thread Five Prime Therapeutics diskutieren
SecteurRecherche biotechnologique et médicale Agenda 13/11 Publication de résultats
Discovers and develops protein therapeutics
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.
The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers.
The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer.
The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that are developing as a monotherapy in multiple cancers.
The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.
The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers.
The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer.
The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that are developing as a monotherapy in multiple cancers.
The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.
Nombre d'employés : 216 personnes.
Stopped prediction by melinda for Five Prime Therapeutics
Five Prime Therapeutics
Start price
Target price
Perf. (%)
€12.11
03.04.19
03.04.19
€18.04
04.11.21
04.11.21
159.21%
05.11.21
05.11.21
Five Prime Therapeutics
Start price
Target price
Perf. (%)
€33.29
03.04.17
03.04.17
€40.59
20.10.17
20.10.17
25.79%
20.10.17
20.10.17